LicianPro

HALOZYME THERAPEUTICS, INC. ·

HALO 8-K 2026-09-30

HALOZYME THERAPEUTICS, INC. (HALO) 8-K dated 2026-09-30 — accession 0001159036-26-000128.

HALOZYME THERAPEUTICS, INC. (HALO) is a biotechnology company listed on US.

HALOZYME THERAPEUTICS, INC. filed a 8-K on 2026-09-30. Accession 0001159036-26-000128.

This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.

Latest reported HALO revenue for 2025-12-31 was $1.40B. Net income was $316.9M. Revenue was up 37.6% from 2024-12-31 to 2025-12-31. HALO currently screens at market cap $7.10B and trailing P/E 28.1.

Not investment advice. The HALO SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr